세계의 고지혈증 시장 보고서(2025년)

Hyperlipidemia Global Market Report 2025

US $ 4,490 ￦ 6,242,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,023,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,803,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 고지혈증 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 예측 기간의 주요 동향에는 신규 치료, 고지혈증 관리에 있어서의 디지털 헬스 기술, 고지혈증 진단 및 치료에서의 바이오마커, 의약품 치료의 연구 개발 활동등이 포함됩니다.

만성 질환, 특히 심장 질환의 이환율이 증가하면 향후 고지혈증 시장의 성장을 이끌 것으로 예상됩니다. 고지혈증 치료는 심장 발작 위험을 줄이고 뇌졸중을 예방하고 내피 기능을 개선하고 침습적 치료의 필요성을 줄임으로써 심장병 환자를 지원합니다. 2024년 9월 영국에 기반을 두는 심장혈관연구 자선단체 British Heart Foundation이 발표한 데이터에 따르면, 영국에서는 약 760만명이 심장 및 순환기 질환을 앓고 있으며, 그 중에는 이러한 질환을 가진 남성 약 400만명, 여성 약 360만명이 포함되어 있다는 것이 밝혀졌습니다. 이러한 질환은 영국에서의 전체 사망의 약 27%를 차지하고, 매년 17만명 이상, 하루 당 약 480명이 사망하고 있어, 3분에 1명이 사망하고 있는 것으로 나타납니다. 그 결과, 심장병 등의 만성 질환의 유병률 증가가 고지혈증 시장의 확대를 촉진하고 있습니다.

흡연률 증가는 향후 고지혈증 시장의 성장을 견인할 것으로 예상됩니다. 흡연은 비만이나 인슐린 저항성 등 고지혈증과 관련된 위험인자와 밀접한 관계가 있습니다. 이러한 위험인자는 지방 수치 이상을 특징으로 하는 지방이상증의 원인이 되며, 궁극적으로 고지혈증의 개발로 이어질 수 있습니다. 예를 들어 캐나다의 정부기관인 캐나다 통계국은 2022년 7월, 2021년 6월과 비교해 담배 생산양이 5.8% 증가하여 2022년 6월에는 담배의 총 판매량이 14억개에 달했다고 보고했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 고지혈증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 고지혈증 시장 : 성장률 분석
• 세계의 고지혈증 시장 실적 : 규모와 성장, 2019-2024
• 세계의 고지혈증 시장 예측 : 규모와 성장, 2024-2029년, 2034F
• 세계의 고지혈증 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 고지혈증 시장 : 유형별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
• 가족성
• 후천성
• 세계의 고지혈증 시장 : 치료별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
• 스타틴
• PCSK9 억제제
• 담즙산 포착제
• 콜레스테롤 흡수 억제제
• 피브린산 유도체
• 조합
• 기타 치료
• 세계의 고지혈증 시장 : 투여 경로별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
• 경구
• 비경구
• 세계의 고지혈증 시장 : 최종 사용자별 분석과 예측, 2019-2024년, 2024-2029F, 2034F
• 병원
• 전문 클리닉
• 홈케어
• 기타 최종 사용자
• 세계의 고지혈증 시장 : 가족성 고지혈증 유형별 세분화, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
• 가족성 고콜레스테롤혈증(FH)
• 가족성 조합 고지혈증
• 가족성 이상 베타 리포단백혈증
• 세계의 고지혈증 시장 : 후천성 고지혈증 유형별 세분화, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
• 다이어트 관련 고지혈증
• 2차 고지혈증
• 약물 유발성 고지혈증

제7장 지역별 및 국가별 분석

• 세계의 고지혈증 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
• 세계의 고지혈증 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 고지혈증 시장 : 경쟁 구도
• 고지혈증 시장 : 기업 프로파일
  • Pfizer Inc. : 개요, 상품 및 서비스, 전략 및 재무분석
  • Johnson and Johnson Limited : 개요, 상품 및 서비스, 전략 및 재무분석
  • Merck and Co. Inc. : 개요, 상품 및 서비스, 전략 및 재무분석
  • AbbVie Inc. : 개요, 상품 및 서비스, 전략 및 재무분석
  • Bayer AG : 개요, 상품 및 서비스, 전략 및 재무분석

제31장 기타 주요 기업 및 혁신 기업

• Novartis AG
• Sanofi-Aventis LLC.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Eli Lilly and Co Ltd.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Sun Pharmaceutical Industries Limited
• Otsuka Pharmaceutical Co. Ltd.
• Menarini Group
• Ipsen SA
• Dr. Reddy's Laboratories Ltd.
• Apotex Inc.
• Hikma Pharmaceuticals PLC

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 고지혈증 시장(2029년) : 새로운 기회를 제공하는 국가
• 고지혈증 시장(2029년) : 새로운 기회를 제공하는 부문
• 고지혈증 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

JHS

영문 목차

영문목차

Hyperlipidemia is a medical condition marked by elevated levels of lipids (fats) in the bloodstream, including cholesterol and triglycerides. This metabolic disorder is common and represents a substantial risk factor for cardiovascular diseases.

Hyperlipidemia can be classified into two main types such as familial and acquired. Familial hyperlipidemia is a genetic disorder characterized by hereditary high lipid levels, notably cholesterol and triglycerides, significantly increasing the risk of cardiovascular diseases. Treatment options encompass medications like statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination therapies, and others. These medications can be administered orally or through injection. They serve various end-users, including hospitals, specialty clinics, home care services, and more.

The hyperlipidemia market research report is one of a series of new reports from The Business Research Company that provides hyperlipidemia market statistics, including hyperlipidemia industry global market size, regional shares, competitors with a hyperlipidemia market share, detailed hyperlipidemia market segments, market trends and opportunities and any further data you may need to thrive in the hyperlipidemia industry. This hyperlipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperlipidemia market size has grown steadily in recent years. It will grow from $20.24 billion in 2024 to $21.03 billion in 2025 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to growing demand for effective treatments, geographic expansion, growing public awareness of hyperlipidemia, tobacco use.

The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $24.3 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to growing demand for hyperlipidemia drugs, global health initiatives, aging population, preventive care and early intervention. Major trends in the forecast period include novel therapies, digital health technologies in hyperlipidemia management, biomarkers in hyperlipidemia diagnosis and treatment, research & development activities of pharmaceuticals treatments.

The rising incidence of chronic disorders, particularly heart disease, is expected to drive the growth of the hyperlipidemia market in the future. Heart diseases encompass various conditions that impact the heart and its functioning. Treatment for hyperlipidemia assists individuals with heart disease by reducing the risk of heart attacks, preventing strokes, improving endothelial function, and decreasing the necessity for invasive procedures. For instance, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, revealed that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including about 4 million males and 3.6 million females living with these conditions. These diseases account for around 27% of all deaths in the UK, resulting in over 170,000 deaths each year, or roughly 480 deaths per day, which translates to one death every three minutes. Consequently, the increasing prevalence of chronic disorders such as heart disease is driving the expansion of the hyperlipidemia market.

The increasing prevalence of smoking is expected to drive the growth of the hyperlipidemia market in the future. Smoking involves the consumption of tobacco through combustion, leading to the inhalation of smoke and the absorption of various components into the bloodstream. Smoking is closely linked to risk factors associated with hyperlipidemia, such as obesity and insulin resistance. These risk factors can contribute to dyslipidemia, characterized by abnormal lipid levels, which can eventually lead to the development of hyperlipidemia. For example, in July 2022, Statistics Canada, a Canadian government agency, reported a 5.8% increase in cigarette production compared to June 2021, with total cigarette sales reaching 1.4 billion in June 2022. Therefore, the growing prevalence of smoking is a driving factor in the hyperlipidemia market.

Key players in the hyperlipidemia market are concentrating on developing innovative products, including advanced therapies for lowering low-density lipoprotein cholesterol, to maintain their market position. For instance, in March 2024, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, announced the approval of Praluent (alirocumab) Injection by the U.S. Food & Drug Administration (FDA). This represents a significant advancement in the treatment of heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 8 and older, providing a targeted method to manage dangerously high low-density lipoprotein cholesterol (LDL-C) levels. The recent FDA approval is backed by Phase 3 trial results, which demonstrated a 31% reduction in LDL-C levels with regular dosing. Its well-established safety profile, consistent with that observed in adults, offers reassurance to families and healthcare providers. Additionally, as the first therapy targeting the genetically-validated PCSK9 protein, Praluent marks a milestone in heart disease treatment. Together, these attributes position Praluent as an essential option for managing high cholesterol in children with HeFH.

In March 2022, Pfizer Inc., a U.S.-based pharmaceutical and biotechnology firm, finalized the acquisition of Arena Pharmaceuticals for an undisclosed sum. This strategic move by Pfizer is driven by the company's goal of broadening its product portfolio through the addition of Arena Pharmaceuticals' ongoing clinical-stage projects, which hold promise for the advancement of innovative therapies targeting various immuno-inflammatory diseases. Arena Pharmaceuticals, situated in the United States, is recognized for its specialization in biopharmaceuticals and the development of medications, including those designed to address high cholesterol and hyperlipidemia.

Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

North America was the largest region in the hyperlipidemia market in 2024. The regions covered in hyperlipidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hyperlipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hyperlipidemia market consists of revenues earned by entities by providing weight management, surgeries and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperlipidemia market also includes sales of niacin (nicotinic acid), omega-3 fatty acid supplements, ezetimibe, resins, adenosine triphosphate-citrate lyase (ACL) inhibitors, lomitapide and mipomersen. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hyperlipidemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hyperlipidemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hyperlipidemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hyperlipidemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Familial; Acquired
• 2) By Treatment: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Combination; Other Treatment
• 3) By Route of Administration: Oral; Parenteral
• 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users
• Subsegments:
• 1) By Familial Hyperlipidemia: Familial Hypercholesterolemia (FH); Familial Combined Hyperlipidemia; Familial Dysbetalipoproteinemia
• 2) By Acquired Hyperlipidemia: Diet-Related Hyperlipidemia; Secondary Hyperlipidemia; Drug-Induced Hyperlipidemia
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; Merck and Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hyperlipidemia Market Characteristics

3. Hyperlipidemia Market Trends And Strategies

4. Hyperlipidemia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hyperlipidemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hyperlipidemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hyperlipidemia Market Growth Rate Analysis
• 5.4. Global Hyperlipidemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hyperlipidemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hyperlipidemia Total Addressable Market (TAM)

6. Hyperlipidemia Market Segmentation

• 6.1. Global Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Familial
• Acquired
• 6.2. Global Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Statins
• PCSK9 Inhibitors
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• Combination
• Other Treatment
• 6.3. Global Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Hyperlipidemia Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End Users
• 6.5. Global Hyperlipidemia Market, Sub-Segmentation Of Familial Hyperlipidemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Familial Hypercholesterolemia (FH)
• Familial Combined Hyperlipidemia
• Familial Dysbetalipoproteinemia
• 6.6. Global Hyperlipidemia Market, Sub-Segmentation Of Acquired Hyperlipidemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diet-Related Hyperlipidemia
• Secondary Hyperlipidemia
• Drug-Induced Hyperlipidemia

7. Hyperlipidemia Market Regional And Country Analysis

• 7.1. Global Hyperlipidemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hyperlipidemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hyperlipidemia Market

• 8.1. Asia-Pacific Hyperlipidemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hyperlipidemia Market

• 9.1. China Hyperlipidemia Market Overview
• 9.2. China Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hyperlipidemia Market

• 10.1. India Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hyperlipidemia Market

• 11.1. Japan Hyperlipidemia Market Overview
• 11.2. Japan Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hyperlipidemia Market

• 12.1. Australia Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hyperlipidemia Market

• 13.1. Indonesia Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hyperlipidemia Market

• 14.1. South Korea Hyperlipidemia Market Overview
• 14.2. South Korea Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hyperlipidemia Market

• 15.1. Western Europe Hyperlipidemia Market Overview
• 15.2. Western Europe Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hyperlipidemia Market

• 16.1. UK Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hyperlipidemia Market

• 17.1. Germany Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hyperlipidemia Market

• 18.1. France Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hyperlipidemia Market

• 19.1. Italy Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hyperlipidemia Market

• 20.1. Spain Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hyperlipidemia Market

• 21.1. Eastern Europe Hyperlipidemia Market Overview
• 21.2. Eastern Europe Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hyperlipidemia Market

• 22.1. Russia Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hyperlipidemia Market

• 23.1. North America Hyperlipidemia Market Overview
• 23.2. North America Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hyperlipidemia Market

• 24.1. USA Hyperlipidemia Market Overview
• 24.2. USA Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hyperlipidemia Market

• 25.1. Canada Hyperlipidemia Market Overview
• 25.2. Canada Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hyperlipidemia Market

• 26.1. South America Hyperlipidemia Market Overview
• 26.2. South America Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hyperlipidemia Market

• 27.1. Brazil Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hyperlipidemia Market

• 28.1. Middle East Hyperlipidemia Market Overview
• 28.2. Middle East Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hyperlipidemia Market

• 29.1. Africa Hyperlipidemia Market Overview
• 29.2. Africa Hyperlipidemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hyperlipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hyperlipidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hyperlipidemia Market Competitive Landscape And Company Profiles

• 30.1. Hyperlipidemia Market Competitive Landscape
• 30.2. Hyperlipidemia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Hyperlipidemia Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi-Aventis LLC.
• 31.3. Bristol-Myers Squibb Company
• 31.4. GlaxoSmithKline plc.
• 31.5. Eli Lilly and Co Ltd.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Daiichi Sankyo Company Limited
• 31.9. Sun Pharmaceutical Industries Limited
• 31.10. Otsuka Pharmaceutical Co. Ltd.
• 31.11. Menarini Group
• 31.12. Ipsen S.A.
• 31.13. Dr. Reddy's Laboratories Ltd.
• 31.14. Apotex Inc.
• 31.15. Hikma Pharmaceuticals PLC

32. Global Hyperlipidemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hyperlipidemia Market

34. Recent Developments In The Hyperlipidemia Market

35. Hyperlipidemia Market High Potential Countries, Segments and Strategies

• 35.1 Hyperlipidemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hyperlipidemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hyperlipidemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료